Bayer Yakuhin to Transfer Baynas Marketing Rights to Nippon Shinyaku.Tokyo, Japan, Apr 24, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Bayer Yakuhin and Nippon Shinyaku have reached an agreement on the sale of Baynas Tablet, Bayer's proprietary anti-allergic rhinitis Rhinitis Definition Rhinitis is inflammation of the mucous lining of the nose. Description Rhinitis is a nonspecific term that covers infections, allergies, and other disorders whose common feature is the location of their symptoms. drug, in Japan. Under the agreement, Bayer Yakuhin will transfer the marketing rights to the agent to Nippon Shinyaku on July 1. Baynas Tablet is an agent that antagonizes prostaglandin D2 and thromboxane thromboxane /throm·box·ane/ (-bok´san) either of two compounds, one designated A2 and the other B2. Thromboxane A2 is synthesized by platelets and is an inducer of platelet aggregation and platelet release functions and is a A2 receptors, which cause allergic rhinitis. Initially launched in May 2005, sales of the agent reached 3 billion yen ($25.3 mil) in 2005. Bayer Yakuhin aims to focus more on a range of cardiovascular risk management (CVRM CVRM Coachella Valley Rescue Mission (Indio, California) CVRM customer value relationship model CVRM Customer/Vendor Relationship Management ) products, its core business, while Nippon Shinyaku will reinforce its product lineup in the inflammation and allergy field. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion